摘要
目的:探讨AMACR在胃癌中的表达及其与临床病理特征之间的关系。方法:应用免疫组化EnVision法检测78例胃癌组织中AMACR/p504s的表达。结果:胃癌组织中AMACR/p504s的阳性表达率为42.3%(33/78)。胃癌中AMACR/p504s的表达在肠型胃癌中表达为61.3%,明显高于弥漫型胃癌29.6%,差异有显著性(P<0.01);AMACR/p504s在高、中和低分化腺癌的阳性表达率分别为73.3%、48.3%和23.5%,差异有显著性(P<0.01)。胃腺癌中AMACR/p504s的表达与肿瘤浸润深度、淋巴结转移和临床分期均无关(P>0.05)。结论:AMACR/p504s的表达与胃癌Lauren分型和分化程度密切相关,可能参与了胃肠型腺癌的发生。
Objective To explore the expression of a-Methylacyl coenzyme A racemase（AMACR） in gastric carcinoma and its relationship with clinicopathologic features. Methods Expression of AMACR in 78 cases of gastric carcinoma were detected by EnVision immunohistochemical technique. Results The expression rate of AMACR/p504s in gastric carcinoma was 42.3% （33/78）. Expression of AMACR/pSO4s in intestinal-type adenocarcinoma was 61.3%,it was higher than that in diffuse-type adenocarcinoma （29.6%,P 〈 0.01）. AMACR/ pSO4s expression in well, moderately, and poorly-differentiated adenocarcinoma were 73.3%, 48.3% and 23.5%, respectively. There was significant difference among three groups （P 〈 0.01）. Expression of AMACR/pS04s in gastric carcinoma was unrelated to the depth of invasion, lymph node metastasis and clinical stage （P 〉 0.05）. Conclusions Expression of AMACR/pSO4s may be correlated with Lauren type and differentiation and may be involved in gastric carcinogenesis.
出处
《实用医学杂志》
CAS
北大核心
2012年第16期2682-2684,共3页
The Journal of Practical Medicine
